Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs EPC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EPC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 10–0 Matrix Metrics)

EPC Overall Winner 6-Pillar Tally: SKIN 2 – 4 EPC Matrix Metrics: SKIN 0 – 10 EPC

As of Nov 16, 2026, Edgewell Personal Care Company (EPC) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas EPC carries 48.4/100 (HOLD) at $28.38 (14.3x Forward P/E, 7.3% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs EPC
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24
EPC NYSE Head-to-Head Winner
Edgewell Personal Care Company
Perfumes, Cosmetics & Other Toilet Preparations
$28.38
+4.03% 1D
Market Cap $1.3B
TTM Revenue $2.00B
Forward P/E 14.3x
Beta / 30D Vol 0.32β · 52% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 42.0 Fund 46.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.4 · SMA20: $28.41 · SMA50: $27.81

6-Pillar Scorecard Institutional Category Breakdown (SKIN 2 – 4 EPC)

Columns: Metric · SKIN · EPC
1. Valuation Multiples EPC
Forward P/E 106.4x 14.3x
Trailing P/E 106.4x 13.5x
PEG Ratio 0.93x 2.87x
EV / Revenue 0.9x 0.6x
2. Growth & Scale EPC
Revenue Growth (YoY) -2.1% +3.0%
Earnings Growth (YoY) +0.0% -53.4%
TTM Revenue (USD) $289M $2.00B
Market Cap $106.3M $1.3B
3. Profitability & Quality EPC
Gross Margin 67.2% 43.0%
Operating Margin 2.4% 7.3%
Net Profit Margin -6.3% -2.6%
Return on Equity (ROE) -30.1% -0.1%
4. Balance Sheet & Cash Flow EPC
Cash Generation (TTM) $17M $218M EBITDA
Cash Flow Margin 5.8% 10.9% EBITDA Mgn
Net Cash / Leverage $161M Net Debt (6.61x D/E) $31.94 Book/Sh · -0.1% ROE
Dividend Yield None (0.00%) 2.09%
5. Options & Positioning SKIN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 517.4% (100th %ile) 40.9% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 35.7% of Rev ($713M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (0) vs EPC (10)
Institutional Metric SKIN EPC Criterion Row Edge
Market Capitalization
Scale
$106.3M $1.3B Larger Scale EPC
Trailing P/E Ratio
Valuation
106.4x 13.5x Lower Multiple EPC
Forward P/E Ratio
Valuation
106.4x 14.3x Lower Multiple EPC
Revenue Growth (YoY)
Growth
-2.1% +3.0% Higher Growth EPC
Operating Margin (TTM)
Profitability
2.4% 7.3% Higher Margin EPC
Net Profit Margin
Profitability
-6.3% -2.6% Higher Margin EPC
Return on Equity (ROE)
Capital Efficiency
-30.1% -0.1% Higher ROE EPC
52-Week Range Position
Momentum
83% ($0–$18) 86% ($16–$30) Stronger Trend EPC
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 0.32β · 52% Vol Lower Realized Risk EPC
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite EPC
Trailing 12M Revenue (USD)
Operating Scale
$289M $2.00B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 43.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev 2.87x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) $218M EBITDA ($31.94 Book/Sh · -0.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +40.84 pp
SKIN: +42.52% · EPC: +1.68%
3M Horizon SKIN +2408.58 pp
SKIN: +2408.33% · EPC: -0.25%
6M Horizon SKIN +2309.3 pp
SKIN: +2385.14% · EPC: +75.84%
1Y Horizon SKIN +1003.37 pp
SKIN: +1057.69% · EPC: +54.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SKIN vs EPC. Trailing 12-month operating profitability (SKIN 2.4% vs EPC 7.3%) and valuation multiples (SKIN 106.4x vs EPC 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

SKIN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$289M
Gross Margin67.2%
Op. Margin2.4%
ROE / Fwd P/E-30.1% · 106.4x
EPC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.00B
Gross Margin43.0%
Op. Margin7.3%
ROE / Fwd P/E-0.1% · 14.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
EPC Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $1.3B market capitalization and 7.3% operating margin.
OpEx & R&D Reinvestment 35.7% of Rev ($713M)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs EPC Key Questions & Quantitative Answers

As of Nov 16, 2026, Edgewell Personal Care Company (EPC) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas EPC carries 48.4/100 (HOLD) at $28.38 (14.3x Forward P/E, 7.3% operating margin). Technically, SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure) and EPC sits in a Neutral phase (RSI 50.4, UNCLASSIFIED options structure).

EPC leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with EPC at +3.0% YoY revenue growth and -53.4% YoY earnings growth on $2.00B TTM revenue (43.0% gross margin, 7.3% operating margin). On trailing 12-month operating scale, SKIN generates $289M in USD-normalized revenue versus $2.00B for EPC. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 35.7% of Rev ($713M) (0 disclosures) for EPC.

EPC screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas EPC trades at 14.3x Forward P/E, 13.5x Trailing P/E, 2.87x PEG, and 0.6x EV/Revenue (10.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus EPC (-0.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, EPC carries 40.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.